Tryptophanyl tRNA synthetase antibody
![Research Use Only](static/images/certificates/ruo.jpg)
GTX110223
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman, Mouse, Rat
TargetWARS1
Overview
- SupplierGeneTex
- Product NameTryptophanyl tRNA synthetase antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- ConjugateUnconjugated
- FormulationLiquid
- Gene ID7453
- Target nameWARS1
- Target descriptiontryptophanyl-tRNA synthetase 1
- Target synonymsepididymis secretory sperm binding protein; GAMMA-2; HMN9; hWRS; IFI53; IFP53; interferon-induced protein 53; trpRS; tryptophan tRNA ligase 1, cytoplasmic; tryptophan--tRNA ligase, cytoplasmic; WARS
- HostRabbit
- IsotypeIgG
- Protein IDP23381
- Protein NameTryptophan--tRNA ligase, cytoplasmic
- Scientific DescriptionAminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Two forms of tryptophanyl-tRNA synthetase exist, a cytoplasmic form, named WARS, and a mitochondrial form, named WARS2. Tryptophanyl-tRNA synthetase (WARS) catalyzes the aminoacylation of tRNA(trp) with tryptophan and is induced by interferon. Tryptophanyl-tRNA synthetase belongs to the class I tRNA synthetase family. Four transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
- ReactivityHuman, Mouse, Rat
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Hagiwara M et al., 2022, OncoimmunologyRead more